Dyadic outlines 2026 product revenue growth and commercialization milestones while expanding partnerships

Q4 2025 earnings call: commercialization shift, new recombinant product launches, partners, 2026 revenue outlook & cash runway.

Worksport outlines $35M–$42M 2026 revenue target as gross margins climb to 30% and new product launches accelerate

Q4 2025 Management View CEO Steven Rossi highlighted that "2025 was a year of real top line growth and significant margin improvement," with full year net sales nearly doubling to $16.1 million and ...

Innovation proves the product works

But innovation alone does not create durability. I have been in boardrooms where the data was strong, projections were bold, ...
Business Insider

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway ...

Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications. Three ...
Seeking Alpha

NeuroOne plans 2026 drug delivery commercialization as Q4 product revenue jumps 907%

Rosa explained the company will issue financial guidance for fiscal 2026 after receiving final projections from Zimmer Biomet. "We plan on providing financial guidance for fiscal year 2026 once we ...
Business Insider

Visionary Holdings (NASDAQ: GV) Provides 2026–2027 Growth Outlook; RAMU Anti-Aging Product Line Targets Potential $30 Million Annual Sales

HONG KONG, March 05, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”), a technology-driven multinational enterprise focused on healthcare services, medical ...